Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Requirements for Translation in Clinical Trials of Aromatherapy: The Case of the Essential Oil of Bergamot (BEO) for Management of Agitation in Severe Dementia

Author(s): Damiana Scuteri*, Shinobu Sakurada, Tsukasa Sakurada, Paolo Tonin, Giacinto Bagetta, Pierluigi Nicotera and Maria Tiziana Corasaniti

Volume 28, Issue 20, 2022

Published on: 02 June, 2022

Page: [1607 - 1610] Pages: 4

DOI: 10.2174/1381612828666220509152029

conference banner
Abstract

Due to the tight link between undertreated pain and agitation in dementia patients, aromatherapy can be a useful approach if an essential oil (EO) with powerful analgesic activity is used. The methodological difficulties of most aromatherapy trials have not allowed any definitive conclusion about the effectiveness of aromatherapy in dementia. The objective of the present perspective is to illustrate the long rigorous process leading from preclinical research to clinical translation of the EO of bergamot (BEO) for the management of agitation in dementia. A nanotechnology-based delivery system consisting of odorless alpha-tocopheryl stearate solid lipid nanoparticles (SLN) loaded with BEO (NanoBEO), has been proven active in acute and neuropathic pain models confirming the strong antinociceptive and anti-allodynic efficacy reported for BEO in preclinical studies. In particular, prolonged physicochemical stability of NanoBEO and titration in its main components are remarkable advantages allowing reproducible antinociceptive and anti-itch responses to be measured. Furthermore, the possibility to perform double-blind clinical trials made impossible so far because of the strong smell of essential oils used in aromatherapy. Demented patients receive limited treatment for chronic pain, particularly neuropathic. The BRAINAID (NCT04321889) trial will assess the effectiveness of NanoBEO on agitation and pain in severely demented patients to offer a safe tool able to provide relief to this fragile population. This double-blind clinical trial will be the first to assess the efficacy and safety of an engineered essential oil and will provide the rationale for the safer treatment of neuropsychiatric symptoms of dementia and pain in clinic.

Keywords: Severe dementia, NPS, agitation, pain, essential oil of bergamot, nanotechnology delivery system.

Next »
[1]
Scuteri D, Piro B, Morrone LA, Corasaniti MT, Vulnera M, Bagetta G. The need for better access to pain treatment: Learning from drug consumption trends in the USA. Funct Neurol 2017; 22(4): 229-30.
[http://dx.doi.org/10.11138/FNeur/2017.32.4.229] [PMID: 29306360]
[2]
Scuteri D, Garreffa MR, Esposito S, Bagetta G, Naturale MD, Corasaniti MT. Evidence for accuracy of pain assessment and painkillers utilization in neuropsychiatric symptoms of dementia in Calabria region, Italy. Neural Regen Res 2018; 13(9): 1619-21.
[http://dx.doi.org/10.4103/1673-5374.237125] [PMID: 30127123]
[3]
Scuteri D, Vulnera M, Piro B, et al. Pattern of treatment of behavioural and psychological symptoms of dementia and pain: Evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia. Eur J Clin Pharmacol 2021; 77(2): 241-9.
[http://dx.doi.org/10.1007/s00228-020-02995-w] [PMID: 32935181]
[4]
Ballard C, Smith J, Husebo B, Aarsland D, Corbett A. The role of pain treatment in managing the behavioural and psychological symp-toms of dementia (BPSD). Int J Palliat Nurs 2011; 17(9): 420.
[5]
Achterberg WP, Pieper MJC, van Dalen-Kok AH, et al. Pain management in patients with dementia. Clin Interv Aging 2013; 8: 1471-82.
[http://dx.doi.org/10.2147/CIA.S36739] [PMID: 24204133]
[6]
Scuteri D, Rombolà L, Morrone LA, et al. Neuropharmacology of the neuropsychiatric symptoms of dementia and role of pain: Essential oil of bergamot as a novel therapeutic approach. Int J Mol Sci 2019; 20(13): E3327.
[http://dx.doi.org/10.3390/ijms20133327] [PMID: 31284573]
[7]
Sampson EL, White N, Lord K, et al. Pain, agitation, and behavioural problems in people with dementia admitted to general hospital wards: A longitudinal cohort study. Pain 2015; 156(4): 675-83.
[http://dx.doi.org/10.1097/j.pain.0000000000000095] [PMID: 25790457]
[8]
Atee M, Morris T, Macfarlane S, Cunningham C. Pain in dementia: prevalence and association with neuropsychiatric behaviors. J Pain Symptom Manage 2021; 61(6): 1215-26.
[http://dx.doi.org/10.1016/j.jpainsymman.2020.10.011] [PMID: 33068708]
[9]
Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294(15): 1934-43.
[http://dx.doi.org/10.1001/jama.294.15.1934] [PMID: 16234500]
[10]
Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009; 5(5): 245-55.
[http://dx.doi.org/10.1038/nrneurol.2009.39] [PMID: 19488082]
[11]
Corbett A, Burns A, Ballard C. Don’t use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ 2014; 349(nov03 1): g6420.
[http://dx.doi.org/10.1136/bmj.g6420] [PMID: 25368388]
[12]
Rajkumar AP, Ballard C, Fossey J, et al. Epidemiology of pain in people with dementia living in care homes: Longitudinal course, prevalence, and treatment implications. J Am Med Directors Assoc 2017; 18(5): 453.e1-.e6.
[13]
Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer’s dis-ease: An international Delphi consensus. Int Psychogeriatr 2019; 31(1): 83-90.
[http://dx.doi.org/10.1017/S1041610218000534] [PMID: 30068400]
[14]
Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: Number needed to harm. JAMA Psychiatry 2015; 72(5): 438-45.
[http://dx.doi.org/10.1001/jamapsychiatry.2014.3018] [PMID: 25786075]
[15]
Yunusa I, El Helou ML. The use of risperidone in behavioral and psychological symptoms of dementia: A review of pharmacology, clinical evidence, regulatory approvals, and off-label use. Front Pharmacol 2020; 11: 596.
[http://dx.doi.org/10.3389/fphar.2020.00596] [PMID: 32528275]
[16]
Ball EL, Owen-Booth B, Gray A, Shenkin SD, Hewitt J, McCleery J. Aromatherapy for dementia. Cochrane Database Syst Rev 2020; 8(8): CD003150.
[PMID: 32813272]
[17]
Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: Cluster randomised clinical trial. BMJ 2011; 343: d4065.
[http://dx.doi.org/10.1136/bmj.d4065] [PMID: 21765198]
[18]
Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia. JAMA 2019; 322(16): 1589-99.
[http://dx.doi.org/10.1001/jama.2019.4782] [PMID: 31638686]
[19]
Lakhan SE, Sheafer H, Tepper D. The effectiveness of aromatherapy in reducing pain: A systematic review and meta-analysis. Pain Res Treat 2016; 2016: 8158693.
[http://dx.doi.org/10.1155/2016/8158693] [PMID: 28070420]
[20]
Scuteri D, Hamamura K, Sakurada T, et al. Efficacy of essential oils in pain: A systematic review and meta-analysis of preclinical evi-dence. Front Pharmacol 2021; 12: 640128.
[http://dx.doi.org/10.3389/fphar.2021.640128] [PMID: 33732159]
[21]
Morrone LA, Rombolà L, Pelle C, et al. The essential oil of bergamot enhances the levels of amino acid neurotransmitters in the hippo-campus of rat: Implication of monoterpene hydrocarbons. Pharmacol Res 2007; 55(4): 255-62.
[http://dx.doi.org/10.1016/j.phrs.2006.11.010] [PMID: 17196823]
[22]
Manns ID, Alonso A, Jones BE. Rhythmically discharging basal forebrain units comprise cholinergic, GABAergic, and putative glutama-tergic cells. J Neurophysiol 2003; 89(2): 1057-66.
[http://dx.doi.org/10.1152/jn.00938.2002] [PMID: 12574480]
[23]
Russo R, Cassiano MG, Ciociaro A, et al. Role of D-Limonene in autophagy induced by bergamot essential oil in SH-SY5Y neuroblas-toma cells. PLoS One 2014; 9(11): e113682.
[http://dx.doi.org/10.1371/journal.pone.0113682] [PMID: 25419658]
[24]
Berliocchi L, Russo R, Maiarù M, Levato A, Bagetta G, Corasaniti MT. Autophagy impairment in a mouse model of neuropathic pain. Mol Pain 2011; 7: 83.
[http://dx.doi.org/10.1186/1744-8069-7-83] [PMID: 22023914]
[25]
Yu WH, Cuervo AM, Kumar A, et al. Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer’s dis-ease. J Cell Biol 2005; 171(1): 87-98.
[http://dx.doi.org/10.1083/jcb.200505082] [PMID: 16203860]
[26]
Scuteri D, Berliocchi L, Rombolà L, et al. Effects of aging on formalin-induced pain behavior and analgesic activity of gabapentin in C57BL/6 Mice. Front Pharmacol 2020; 11: 663.
[http://dx.doi.org/10.3389/fphar.2020.00663] [PMID: 32457634]
[27]
Parcon PA, Balasubramaniam M, Ayyadevara S, et al. Apolipoprotein E4 inhibits autophagy gene products through direct, specific bind-ing to CLEAR motifs. Alzheimers Dement 2018; 14(2): 230-42.
[http://dx.doi.org/10.1016/j.jalz.2017.07.754] [PMID: 28945989]
[28]
Hu C, Chen C, Dong XP. Impact of COVID-19 pandemic on patients with neurodegenerative diseases. Front Aging Neurosci 2021; 13: 664965.
[http://dx.doi.org/10.3389/fnagi.2021.664965] [PMID: 33897410]
[29]
Kuo CL, Pilling LC, Atkins JL, et al. APOE E4 genotype predicts severe COVID-19 in the UK biobank community cohort. J Gerontol A Biol Sci Med Sci 2020; 75(11): 2231-2.
[http://dx.doi.org/10.1093/gerona/glaa131] [PMID: 32451547]
[30]
Scuteri D, Matamala-Gomez M, Bottiroli S, et al. Pain assessment and treatment in dementia at the time of coronavirus disease COVID-19. Front Neurol 2020; 11: 890.
[http://dx.doi.org/10.3389/fneur.2020.00890] [PMID: 32982921]
[31]
Rombolà L, Scuteri D, Watanabe C, et al. Role of 5-HT1A receptor in the anxiolytic-relaxant effects of bergamot essential oil in rodent. Int J Mol Sci 2020; 21(7): E2597.
[http://dx.doi.org/10.3390/ijms21072597] [PMID: 32283606]
[32]
Rombolà L, Scuteri D, Adornetto A, et al. Anxiolytic-like effects of bergamot essential oil are insensitive to flumazenil in rats. Evidence-based Comp Alter Med 2019; 2019: 2156873.
[http://dx.doi.org/10.1155/2019/2156873]
[33]
Bagetta G, Morrone LA, Rombolà L, et al. Neuropharmacology of the essential oil of bergamot. Fitoterapia 2010; 81(6): 453-61.
[http://dx.doi.org/10.1016/j.fitote.2010.01.013] [PMID: 20093169]
[34]
Kuwahata H, Komatsu T, Katsuyama S, et al. Peripherally injected linalool and bergamot essential oil attenuate mechanical allodynia via inhibiting spinal ERK phosphorylation. Pharmacol Biochem Behav 2013; 103(4): 735-41.
[http://dx.doi.org/10.1016/j.pbb.2012.11.003] [PMID: 23159543]
[35]
Hamamura K, Katsuyama S, Komatsu T, et al. Behavioral effects of continuously administered bergamot essential oil on mice with par-tial sciatic nerve ligation. Front Pharmacol 2020; 11: 1310.
[http://dx.doi.org/10.3389/fphar.2020.01310] [PMID: 32973528]
[36]
Sakurada T, Mizoguchi H, Kuwahata H, et al. Intraplantar injection of bergamot essential oil induces peripheral antinociception mediated by opioid mechanism. Pharmacol Biochem Behav 2011; 97(3): 436-43.
[http://dx.doi.org/10.1016/j.pbb.2010.09.020] [PMID: 20932858]
[37]
Scuteri D, Crudo M, Rombolà L, et al. Antinociceptive effect of inhalation of the essential oil of bergamot in mice. Fitoterapia 2018; 129: 20-4.
[http://dx.doi.org/10.1016/j.fitote.2018.06.007] [PMID: 29906556]
[38]
Scuteri D, Cassano R, Trombino S, et al. Development and translation of nanobeo, a nanotechnology-based delivery system of bergamot essential oil deprived of furocumarins, in the control of agitation in severe dementia. Pharmaceutics 2021; 13(3): 379.
[http://dx.doi.org/10.3390/pharmaceutics13030379] [PMID: 33809385]
[39]
Scuteri D, Sandrini G, Tamburin S, et al. Bergamot rehabilitation AgaINst agitation in dementia (BRAINAID): Study protocol for a ran-domized, double-blind, placebo-controlled trial to assess the efficacy of furocoumarin-free bergamot loaded in a nanotechnology-based delivery system of the essential oil in the treatment of agitation in elderly affected by severe dementia. Phytother Res 2021; 35(10): 5333-8.
[http://dx.doi.org/10.1002/ptr.7223] [PMID: 34435395]
[40]
Gibson SJ, Voukelatos X, Ames D, Flicker L, Helme RD. An examination of pain perception and cerebral event-related potentials follow-ing carbon dioxide laser stimulation in patients with Alzheimer’s disease and age-matched control volunteers. Pain Res Manag 2001; 6(3): 126-32.
[http://dx.doi.org/10.1155/2001/814374] [PMID: 11854775]
[41]
Corbett A, Husebo B, Malcangio M, et al. Assessment and treatment of pain in people with dementia. Nat Rev Neurol 2012; 8(5): 264-74.
[http://dx.doi.org/10.1038/nrneurol.2012.53] [PMID: 22487749]
[42]
Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol 1989; 44(3): M77-84.
[http://dx.doi.org/10.1093/geronj/44.3.M77] [PMID: 2715584]
[43]
Husebo BS, Strand LI, Moe-Nilssen R, Husebo SB, Ljunggren AE. Pain in older persons with severe dementia. Psychometric properties of the Mobilization-Observation-Behaviour-Intensity-Dementia (MOBID-2) Pain Scale in a clinical setting. Scand J Caring Sci 2010; 24(2): 380-91.
[http://dx.doi.org/10.1111/j.1471-6712.2009.00710.x] [PMID: 20210897]
[44]
Agostini M, Moja L, Banzi R, et al. Telerehabilitation and recovery of motor function: A systematic review and meta-analysis. J Telemed Telecare 2015; 21(4): 202-13.
[http://dx.doi.org/10.1177/1357633X15572201] [PMID: 25712109]
[45]
Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, et al. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother 2022; 146: 112505.
[http://dx.doi.org/10.1016/j.biopha.2021.112505]
[46]
Modi D, Mohammad, Warsi MH, et al. Formulation development, optimization, and in vitro assessment of thermoresponsive ophthalmic pluronic F127-chitosan in situ tacrolimus gel. J Biomater Sci Polym Ed 2021; 32(13): 1678-702.
[http://dx.doi.org/10.1080/09205063.2021.1932359] [PMID: 34013840]

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy